{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2007"],"condition":["","UNRESECTABLE LIVER METASTASES FROM COLORECTAL CANCER"],"disease":["","Unresectable Liver Metastases From Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2522576"],"location":["Italy"],"study_start_month":["5"],"keyword":["CAMPTO","AVASTIN","FLUOROURACILE TEVA","ELOXATIN","LEDERFOLIN"],"repository":["ECRIN MDR"],"study_status":["Ongoing"],"additional_accession":[]},"is_claimable":false,"name":"PHASE II TRIAL OF FOLFIRI REGIMEN PLUS BEVACIZUMAB ALTERNATED WITH OXALIPLATIN-BASED HEPATIC ARTERIAL INFUSION PLUS DE GRAMONT REGIMEN AND BEVACIZUMAB IN THE TREATMENT OF UNRESECTABLE LIVER METASTASES FROM COLORECTAL CANCER","description":"Primary objectives: TUMOR RESPONSE RATE (RR)","dates":{"creation":"2007-05-15"},"accession":"2522576","cross_references":{"EU Clinical Trials Register":["2007-003484-45"]}}